TVTX
Travere Therapeutics, Inc.
TVTX lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
TVTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Strong |
TVTX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
TVTX PE Valuation
TVTX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
TVTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TVTX to return to profit, with revenue growing. However, they disagree widely on these estimates.
TVTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.94 | — |
| Q3 2026 | -$1.28 | -$0.24 |
| Q2 2026 | -$0.45 | +$1.57 |
| Q1 2026 | -$0.22 | +$2.57 |
| Q4 2025 | -$0.29 | +$3.79 |
| Q3 2025 | -$1.04 | +$3.51 |
| Q2 2025 | -$2.02 | -$0.14 |
| Q1 2025 | -$2.79 | -$0.69 |
| Q4 2024 | -$4.08 | -$2.47 |
TVTX is still losing money, but far less than before: $1.28 per share over the past year, against $4.56 at its worst in late 2021.
TVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $224.6M | +36% |
| Q2 2026 | $169.6M | +48% |
| Q1 2026 | $127.2M | +56% |
| Q4 2025 | $129.7M | +73% |
| Q3 2025 | $164.9M | +162% |
| Q2 2025 | $114.4M | +111% |
| Q1 2025 | $81.7M | +98% |
| Q4 2024 | $74.8M | +66% |
TVTX's revenue has grown year over year for nine quarters in a row: $225M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | -45 points |
| Q2 2026 | 2.3% | +13 points |
| Q1 2026 | -29% | +23 points |
| Q4 2025 | -25% | +56 points |
| Q3 2025 | 15% | +104 points |
| Q2 2025 | -11% | +114 points |
| Q1 2025 | -52% | +284 points |
| Q4 2024 | -81% | +128 points |
TVTX's operating margin was −30% last quarter, down 45 points from the same quarter a year ago.
TVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$40.4M | +$1.8M |
| Q4 2025 | $60.7M | +$96.4M |
| Q3 2025 | $14.2M | +$56.7M |
| Q1 2025 | -$42.2M | +$76.8M |
| Q4 2024 | -$35.7M | +$34.8M |
| Q2 2024 | -$40.3M | +$29M |
| Q1 2024 | -$119M | -$37.3M |
| Q4 2023 | -$70.5M | -$15.8M |
TVTX's free cash flow has turned positive after five years mostly in the red: $93M over the past year.
TVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | -7.8% | -8M shares |
| 3 years | +24% | +18.3M shares |
| 5 years | +56% | +33.8M shares |
| Available history | +123% | +52.3M shares |
TVTX has 95M diluted shares, down 7.8% from a year ago.
TVTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -5.1x | Net Cash |
| Q1 2026 | -4.9x | Net Cash |
TVTX has more cash than debt.
TVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 18.2 | Oversold |
TVTX's weekly RSI is 48 (neutral) and its Stochastic is 18 (oversold).
TVTX PE vs Healthcare Sector
TVTX has no meaningful PE right now: it lost money over the past year.
TVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.5 | 1.7% below |
| 20 week MA | $57.6 | 11% below |
| 50 week MA | $45.2 | 14% above |
| 100 week MA | $32.9 | 57% above |
| 200 week MA | $22.8 | 126% above |
TVTX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 126% above its 200-week average.
TVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $27.6 | +92% |
| 2021 | $27.6 | $31.2 | +13% |
| 2022 | $31.2 | $20.0 | -36% |
| 2023 | $20.0 | $8.99 | -55% |
| 2024 | $8.99 | $17.3 | +92% |
| 2025 | $17.3 | $39.6 | +129% |
| 2026 YTD | $39.6 | $51.6 | +30% |
TVTX's yearly returns have swung widely, from +129% in 2025 to −55% in 2023. It's up 30% so far in 2026.